The role of natural killer T cells in B cell malignancies

Tumor Biology

Volumn 34, Issue 3, 2013, Pages 1349-1360

  Ghalamfarsa, Ghasem ^a   Hadinia, Abolghasem ^a   Yousefi, Mehdi ^b   Jadidi Niaragh, Farhad ^c  

^a YASUJ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

B cell malignancies; Leukemia; Lymphoma; Natural killer T cells; NKT

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1 ANTIGEN;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CANCER IMMUNIZATION; CARCINOGENESIS; CELLULAR DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; NATURAL KILLER T CELL; NATURAL KILLER T CELL LIKE CELL; NATURAL KILLER T CELL TYPE I; NATURAL KILLER T CELL TYPE II; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 84878743406     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0743-x     Document Type: Review

References (108)

1. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235-71.
2. Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383-93.
3. Motohashi S, Nakayama T. Clinical applications of natural killer t cell-based immunotherapy for cancer. Cancer science. 2008;99:638-45.
4. Giaccone G, Punt CJA, Ando Y, Ruijter R, Nishi N, Peters M, et al. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res. 2002;8:3702-9.
5. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer. 2002;2:850-61.
6. Makino Y, Kanno R, Ito T, Higashino K, Taniguchi M. Predominant expression of invariant Vα14+ TCH α chain in NK1.1+ T cell populations. Int Immunol. 1995;7:1157-61.
7. Ceredig R, Lynch F, Newman P. Phenotypic properties, interleukin 2 production, and developmental origin of a "mature" subpopulation of Lyt-2-L3T4-mouse thymocytes. Proc Natl Acad Sci. 1987;84:8578-82.
8. Fowlkes B, Kruisbeek A, Ton-That H, Weston M, Coligan J, Schwartz R, Pardoll D: A novel population of T-cell receptor αβ-bearing thymocytes which predominantly expresses a single Vβ gene family. Nature 1987;329(6136):251-4.
9. Godfrey DI, Hammond KJL, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today. 2000;21:573-83.
10. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol. 2004;4:231-7.
11. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297-336.
12. Uldrich AP, Patel O, Cameron G, Pellicci DG, Day EB, Sullivan LC, et al. A semi-invariant V [alpha] 10+ T cell antigen receptor defines a population of natural killer T cells with distinct glycolipid antigen-recognition properties. Nat Immunol. 2011;12:616-23.
13. Gadola SD, Dulphy N, Salio M, Cerundolo V. Vα24-JαQ- independent, CD1d-restricted recognition of α-galactosylceramide by human CD4+ and CD8αβ + T lymphocytes. J Immunol. 2002;168:5514-20.
14. Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol. 2010;11:197-206.
15. Hammond KJL, Pelikan SB, Crowe NY, Randle-Barrett E, Nakayama T, Taniguchi M, et al. NKT cells are phenotypically and functionally diverse. Eur J Immunol. 1999;29:3768-81.
16. Kronenberg M. Toward an understanding of NKT cell biology: Progress and paradoxes. Annu Rev Immunol. 2005;26:877-900.
17. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol. 2002;2:557-68.
18. Cardell S, Tangri S, Chan S, Kronenberg M, Benoist C, Mathis D. CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice. The Journal of experimental medicine. 1995;182:993-1004.
19. Van Rhijn I, Young DC, Im JS, Levery SB, Illarionov PA, Besra GS, et al. CD1d-restricted T cell activation by nonlipidic small molecules. Proc Natl Acad Sci U S A. 2004;101:13578-83.
20. Roy KC, Maricic I, Khurana A, Smith TRF, Halder RC, Kumar V. Involvement of secretory and endosomal compartments in presentation of an exogenous self-glycolipid to type II NKT cells. J Immunol. 2008;180:2942-50.
21. Blomqvist M, Rhost S, Teneberg S, Löfbom L, Østerbye T, Brigl M, et al. Multiple tissue-specific isoforms of sulfatide activate CD1d-restricted type II NKT cells. Eur J Immunol. 2009;39:1726-35.
22. Kenna T, Mason LG, Porcelli SA, Koezuka Y, Hegarty JE, O'Farrelly C, et al. Nkt cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J Immunol. 2003;171:1775-9.
23. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F, et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature. 2003;422:164-9.
24. Park SH, Benlagha K, Lee D, Balish E, Bendelac A. Unaltered phenotype, tissue distribution and function of Vα14+ NKT cells in germ-free mice. Eur J Immunol. 2000;30:620-5.
25. Schrantz N, Sagiv Y, Liu Y, Savage PB, Bendelac A, Teyton L. The Niemann-Pick type C2 protein loads isoglobotrihexosylceramide onto CD1d molecules and contributes to the thymic selection of NKT cells. The Journal of experimental medicine. 2007;204:841-52.
26. Carding SR, Egan PJ. Γδ T cells: functional plasticity and heterogeneity. Nat Rev Immunol. 2002;2:336-45.
27. Lees RK, Ferrero I, MacDonald HR. Tissue-specific segregation of TCRγ δ + NKT cells according to phenotype TCR repertoire and activation status: parallels with TCR α β + NKT cells. Eur J Immunol. 2001;31:2901-9.
28. Lanier L, Le AM, Civin C, Loken M, Phillips J. The relationship of D16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood nk cells and cytotoxic T lymphocytes. J Immunol. 1986;136:4480-6.
29. Schmidt RE, Murray C, Daley JF, Schlossman S, Ritz J. A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. The Journal of experimental medicine. 1986;164:351-6.
30. Ortaldo JR, Winkler-Pickett RT, Yagita H, Young HA. Comparative studies of CD3-and CD3+ CD56+ cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression. Cell Immunol. 1991;136:486.
31. Elewaut D, Kronenberg M. Molecular biology of NK T cell specificity and development. Semin Immunol. 2000;12(6):561-8.
32. Golden-Mason L, Castelblanco N, O'Farrelly C, Rosen HR. Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis cC virus infection. J Virol. 2007;81:9292-8.
33. Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L. CD1d-restricted iNKT cells, the 'Swiss-army knife'of the immune system. Curr Opin Immunol. 2008;20:358-68.
34. Doherty DG, Norris S, Madrigal-Estebas L, McEntee G, Traynor O, Hegarty JE, et al. The human liver contains multiple populations of NK cells, T cells, and CD3+ CD56+ natural T cells with distinct cytotoxic activities and Th1, Th2, And Th0 cytokine secretion patterns. J Immunol. 1999;163:231-2321.
35. Satoh M, Seki S, Hashimoto W, Ogasawara K, Kobayashi T, Kumagai K, et al. Cytotoxic gammadelta or alphabeta t cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. J Immunol. 1996;157:3886-92.
36. Jadidi-Niaragh F, Jeddi-Tehrani M, Ansaripour B, Razavi SM, Sharifian RA, Shokri F. Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia. Medical Oncology. 2012;29:3561-9.
37. Guven H, Gilljam M, Chambers B, Ljunggren H, Christensson B, Kimby E, et al. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with b-chronic lymphocytic leukemia (b-CLL): a potential source for cellular immunotherapy. Leukemia. 2003;17:1973-80.
38. Wei DG, Lee H, Park SH, Beaudoin L, Teyton L, Lehuen A, et al. Expansion and long-range differentiation of the NKT cell lineage in mice expressing CD1d exclusively on cortical thymocytes. The Journal of experimental medicine. 2005;202:239-48.
39. Coles MC, Raulet DH. NK1.1+ T cells in the liver arise in the thymus and are selected by interactions with class I molecules on CD4+ CD8+ cells. J Immunol. 2000;164:2412-8.
40. Godfrey DI, Berzins SP. Control points in nkt-cell development. Nat Rev Immunol. 2007;7:505-18.
41. Bezbradica JS, Hill T, Stanic AK, Van Kaer L, Joyce S. Commitment toward the natural t (inkt) cell lineage occurs at the CD4+ 8+ stage of thymic ontogeny. Proc Natl Acad Sci U S A. 2005;102:5114-9.
42. Nichols KE, Hom J, Gong SY, Ganguly A, Ma CS, Cannons JL, et al. Regulation of NKT cell development by SAP, the protein defective in XLP. Nature medicine. 2005;11:340-5.
43. Kovalovsky D, Uche OU, Eladad S, Hobbs RM, Yi W, Alonzo E, et al. The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol. 2008;9:1055-64.
44. Savage AK, Constantinides MG, Han J, Picard D, Martin E, Li B, et al. The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity. 2008;29:391-403.
45. Kreslavsky T, Savage AK, Hobbs R, Gounari F, Bronson R, Pereira P, et al. TCR-inducible PLZF transcription factor required for innate phenotype of a subset of γδ T cells with restricted TCR diversity. Proc Natl Acad Sci. 2009;106:12453-8.
46. Stanic AK, Bezbradica JS, Park JJ, Matsuki N, Mora AL, Van Kaer L, et al. NF-κb controls cell fate specification, survival, and molecular differentiation of immunoregulatory natural T lymphocytes. J Immunol. 2004;172:2265-73.
47. Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, Pellicci DG, et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. The Journal of experimental medicine. 2005;202:1279-88.
48. Eberl G, Lees R, Smiley ST, Taniguchi M, Grusby MJ, MacDonald HR. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells. J Immunol. 1999;162:6410-9.
49. Zeng D, Gazit G, Dejbakhsh-Jones S, Balk SP, Snapper S, Taniguchi M, et al. Heterogeneity of NK1.1+ T cells in the bone marrow: divergence from the thymus. J Immunol. 1999;163:5338-45.
50. Dougan SK, Rava P, Hussain MM, Blumberg RS. MTP regulated by an alternate promoter is essential for NKT cell development. The Journal of experimental medicine. 2007;204:533-45.
51. Hussain MM, Rava P, Pan X, Dai K, Dougan SK, Iqbal J, et al. Microsomal triglyceride transfer protein in plasma and cellular lipid metabolism. Curr Opin Lipidol. 2008;19:277-84.
52. Barral DC, Brenner MB. CD1 antigen presentation: how it works. Nat Rev Immunol. 2007;7:929-41.
53. Motoki K, Morita M, Kobayashi E, Uchida T, Akimoto K, Fukushima H, Koezuka Y. Immunostimulatory and antitumor activities of monoglycosylceramides having various sugar moieties. Biol Pharm Bull. 1995;18(11):1487-91.
54. Morita M, Motoki K, Akimoto K, Natori T, Sakai T, Sawa E, et al. Structure-activity relationship of. Alpha-galactosylceramides against B16-bearing mice. J Med Chem. 1995;38:2176-87.
55. Toura I, Kawano T, Akutsu Y, Nakayama T, Ochiai T, Taniguchi M. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J Immunol. 1999;163:2387-91.
56. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. The Journal of experimental medicine. 2002;196:119-27.
57. Stewart TJ, Smyth MJ, Fernando GJP, Frazer IH, Leggatt GR. Inhibition of early tumor growth requires Jα18-positive (natural killer T) cells. Cancer Res. 2003;63:3058-60.
58. Schmieg J, Yang G, Franck RW, Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. The Journal of experimental medicine. 2003;198:1631-41.
59. Tahir SMA, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, et al. Loss of IFN-γ production by invariant NK T cells in advanced cancer. J Immunol. 2001;167:4046-50.
60. Hix LM, Shi YH, Brutkiewicz RR, Stein PL, Wang CR, Zhang M. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. PLoS One. 2011;6:e20702.
61. Park JM, Terabe M, van den Broeke LT, Donaldson DD, Berzofsky JA. Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. Int J Cancer. 2004;114:80-7.
62. Alves P. De Angelo Andrade L, Petta C, Lorand-Metze I, Derchain S, Guimarães F: Ex vivo expansion of CD56+ NK and NKT-like lymphocytes from peripheral blood mononuclear cells of patients with ovarian neoplasia. Scand J Immunol. 2011;74:244-52.
63. Miura S, Kawana K, Schust DJ, Fujii T, Yokoyama T, Iwasawa Y, et al. CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV. J Virol. 2010;84:11614-23.
64. Motohashi S, Okamoto Y, Yoshino I, Nakayama T. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clin Immunol. 2011;140:167-76.
65. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012;12:239-52.
66. Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii SI, Dhodapkar KM, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. The Journal of experimental medicine. 2003;197:1667-76.
67. Song W, van der Vliet HJJ, Tai YT, Prabhala R, Wang R, Podar K, et al. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res. 2008;14:6955-62.
68. Weinkove R, Brooks CR, Carter JM, Hermans IF, Ronchese F: Functional invariant natural killer T cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy. Haematologica 2012
69. Yoneda K-i, Morii T, Nieda M, Tsukaguchi N, Amano I, Tanaka H, et al. The peripheral blood vα24+ NKT cell numbers decrease in patients with haematopoietic malignancy. Leuk Res. 2005;29:147-52.
70. Renukaradhya GJ, Khan MA, Vieira M, Du W, Gervay-Hague J, Brutkiewicz RR. Type i nkt cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a b-cell lymphoma. Blood. 2008;111:5637-45.
71. Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res. 2008;101:277-348.
72. Molling JW, Kölgen W, van der Vliet HJJ, Boomsma MF, Kruizenga H, Smorenburg CH, et al. Peripheral blood IFN-γ-secreting Vα24+ Vβ11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer. 2005;116:87-93.
73. Azuma T, Takahashi T, Kunisato A, Kitamura T, Hirai H. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res. 2003;63:4516-20.
74. Cava AL, Kaer LV. CD4+ CD25+ Tregs and NKT cells: regulators regulating regulators. Trends in immunology. 2006;27:322-7.
75. King MA, Radicchi-Mastroianni MA. Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4-colour flow cytometry. Cytometry. 1996;26:121-4.
76. Bojarska-Junak A, Hus I, Sieklucka M, Wasik-Szczepanek E, Mazurkiewicz T, Polak P, et al. Natural killer-like T CD3+/CD16+ CD56+ cells in chronic lymphocytic leukemia: intracellular cytokine expression and relationship with clinical outcome. Oncology reports. 2010;24:803.
77. Gibson SE, Swerdlow SH, Felgar RE. Natural killer cell subsets and natural killer-like T-cell populations in benign and neoplastic B-cell proliferations vary based on clinicopathologic features. Hum Pathol. 2011;42:679-87.
78. Hus I, Starosławska E, Bojarska-Junak A, Dobrzyńska- Rutkowska A, Surdacka A, Wdowiak P, et al. CD3+/CD16+ CD56+ cell numbers in peripheral blood are correlated with higher tumor burden in patients with diffuse large B-cell lymphoma. Folia Histochemica et Cytobiologica. 2011;49:183-7.
79. Christopoulos P, Pfeifer D, Bartholomé K, Follo M, Timmer J, Fisch P, et al. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood. 2011;117:3836-46.
80. Jadidi-Niaragh F, Ghalamfarsa G, Memarian A, Asgarian-Omran H, Razavi S, Sarrafnejad A, F. S: Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia. Tumour Biology 2012
81. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol. 1999;163:4647-50.
82. Metelitsa LS, Naidenko OV, Kant A, Wu HW, Loza MJ, Perussia B, et al. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol. 2001;167:3114-22.
83. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide- loaded DCs. Nat Immunol. 2002;3:867-74.
84. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, et al. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. The Journal of experimental medicine. 1999;189:1121-8.
85. Fais F, Tenca C, Cimino G, Coletti V, Zanardi S, Bagnara D, et al. CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia. 2005;19:551-6.
86. Dhodapkar KM, Cirignano B, Chamian F, Zagzag D, Miller DC, Finlay JL, et al. Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer. 2004;109:893-9.
87. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162-74.
88. Nieda M, Nicol A, Koezuka Y, Kikuchi A, Lapteva N, Tanaka Y, et al. Trail expression by activated human CD4+ Vα24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood. 2001;97:2067-74.
89. Brigl M, Brenner MB. Cd1: Antigen presentation and T cell function. Annu Rev Immunol. 2004;22:817-90.
90. Haraguchi K, Takahashi T, Nakahara F, Matsumoto A, Kurokawa M, Ogawa S, et al. CD1d expression level in tumor cells is an important determinant for anti-tumor immunity by natural killer T cells. Leukemia & lymphoma. 2006;47:2218-23.
91. Fais F, Morabito F, Stelitano C, Callea V, Zanardi S, Scudeletti M, et al. CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates α-galactosylceramide presentation to natural killer T lymphocytes. Int J Cancer. 2004;109:402-11.
92. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res. 1995;7:529.
93. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science. 1997;278:1626-9.
94. Mattarollo SR, West AC, Steegh K, Duret H, Paget C, Martin B, Matthews GM, Shortt J, Chesi M, Leif P: NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B cell lymphoma. Blood 2012
95. Smyth MJ, Thia KYT, Street SEA, Cretney E, Trapani JA, Taniguchi M, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. The Journal of experimental medicine. 2000;191:661-8.
96. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science. 1997;278:1623-6.
97. Galili U, Clark MR, Shohet SB, Buehler J, Macher BA. Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1-3Gal epitope in primates. Proc Natl Acad Sci. 1987;84:1369-73.
98. Yoshimura N, Sawada T, Furusawa M, Fuchinoue S. Expression of xenoantigen transformed human cancer cells to be susceptible to antibody-mediated cell killing. Cancer Lett. 2001;164:155-60.
99. Thomas SY, Hou R, Boyson JE, Means TK, Hess C, Olson DP, et al. CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J Immunol. 2003;171:2571-80.
100. Bagnara D, Ibatici A, Corselli M, Sessarego N, Tenca C, De Santanna A, et al. Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms. Haematologica. 2009;94:967-74.
101. Lefterova P, Schakowski F, Buttgereit P, Scheffold C, Huhn D, Schmidt-Wolf I. Expansion of CD3+ CD56+ cytotoxic cells from patients with chronic lymphocytic leukemia: in vitro efficacy. Haematologica. 2000;85:1108-9.
102. Gustafsson K, Junevik K, Werlenius O, Holmgren S, Karlsson-Parra A, Andersson PO. Tumour-loaded α-type 1-polarized dendritic cells from patients with chronic lymphocytic leukaemia produce a superior NK, NKT and CD8+ T cell-attracting chemokine profile. Scand J Immunol. 2011;74:318-26.
103. Kim CH, Johnston B, Butcher EC. Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among Vα24+ Vβ11+ NKT cell subsets with distinct cytokine-producing capacity. Blood. 2002;100:11-6.
104. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006;108:618-21.
105. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-8.
106. Sriram V, Cho S, Li P, O'Donnell PW, Dunn C, Hayakawa K, et al. Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells. Proc Natl Acad Sci. 2002;99:8197-202.
107. Chang DH, Deng H, Matthews P, Krasovsky J, Ragupathi G, Spisek R, et al. Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer. Blood. 2008;112:1308-16.
108. Dhodapkar MV, Richter J. Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. Clin Immunol. 2011;140:160-6.